Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.83 Average Price Target from Analysts

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been assigned an average rating of “Hold” from the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.8333.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th.

Cardiff Oncology Stock Up 2.8%

NASDAQ CRDF opened at $2.57 on Wednesday. The firm has a market cap of $173.12 million, a P/E ratio of -3.25 and a beta of 1.35. Cardiff Oncology has a 52-week low of $1.90 and a 52-week high of $4.99. The business’s 50-day moving average price is $2.25 and its 200 day moving average price is $2.66.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. As a group, analysts anticipate that Cardiff Oncology will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors have recently added to or reduced their stakes in the business. Jeppson Wealth Management LLC acquired a new position in Cardiff Oncology during the 3rd quarter worth approximately $25,000. Brooklyn Investment Group purchased a new stake in shares of Cardiff Oncology in the third quarter valued at approximately $26,000. Baader Bank Aktiengesellschaft acquired a new position in Cardiff Oncology during the second quarter worth $32,000. Belpointe Asset Management LLC acquired a new position in Cardiff Oncology during the first quarter worth $37,000. Finally, Integrity Alliance LLC. purchased a new position in Cardiff Oncology in the second quarter worth $41,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.